Inflammatory bowel diseases · 2026
Effect of polydeoxyribonucleotide as a potential therapeutic agent to enhance the healing of Crohn's perianal fistula.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Hyeon Kyeong, Yoon Yong Sik, Lee Jong Lyul, Park Eun Jung, Kim Min Hyun, Kim Young Il, Kim Chan Wook, Park In Ja, Lim Seok-Byung, Yu Chang Sik
Аннотация
BACKGROUND: The treatment of Crohn's perianal fistula remains challenging owing to its recurrent nature and resistance to complete healing. This study aimed to assess the postoperative outcomes, including fistula closure rates, following Crohn's perianal fistula surgery, with and without polydeoxyribonucleotide administration.
METHODS: A retrospective review was conducted on patients who underwent fistula closure operations for Crohn's perianal fistula at a single tertiary center in Seoul, Korea, between January 2018 and June 2024. Patients were divided into two groups based on the use of local polydeoxyribonucleotide (PDRN) injections during fistula closure operations, and clinical variables and postoperative outcomes were compared between the groups.
RESULTS: Among the 47 patients, 21 (44.7%) were assigned to the PDRN group and 26 (55.3%) were assigned to non-PDRN group. Baseline characteristics between the two groups showed no significant difference. During the mean follow-up of 30.4 months, patients in the PDRN group demonstrated a significantly higher complete fistula closure rate (70.0% vs 26.9% at 6 months, and 83.3% vs 46.2% at 12 months; P = .005), and a shorter time from surgery to complete closure (3.3 ± 2.6 months vs 5.9 ± 3.8 months; P = .044), compared with the non-PDRN group. Multivariate analysis revealed PDRN as an independent factor significantly associated with Crohn's perianal fistula closure (HR 2.336; 95% CI, 1.092-4.997, P = .029).
CONCLUSIONS: PDRN is a potential therapeutic agent that presents a viable option for Crohn's perianal fistula surgery, improving complete fistula closure rate through a safe, cost-effective, and relatively simple procedure.
METHODS: A retrospective review was conducted on patients who underwent fistula closure operations for Crohn's perianal fistula at a single tertiary center in Seoul, Korea, between January 2018 and June 2024. Patients were divided into two groups based on the use of local polydeoxyribonucleotide (PDRN) injections during fistula closure operations, and clinical variables and postoperative outcomes were compared between the groups.
RESULTS: Among the 47 patients, 21 (44.7%) were assigned to the PDRN group and 26 (55.3%) were assigned to non-PDRN group. Baseline characteristics between the two groups showed no significant difference. During the mean follow-up of 30.4 months, patients in the PDRN group demonstrated a significantly higher complete fistula closure rate (70.0% vs 26.9% at 6 months, and 83.3% vs 46.2% at 12 months; P = .005), and a shorter time from surgery to complete closure (3.3 ± 2.6 months vs 5.9 ± 3.8 months; P = .044), compared with the non-PDRN group. Multivariate analysis revealed PDRN as an independent factor significantly associated with Crohn's perianal fistula closure (HR 2.336; 95% CI, 1.092-4.997, P = .029).
CONCLUSIONS: PDRN is a potential therapeutic agent that presents a viable option for Crohn's perianal fistula surgery, improving complete fistula closure rate through a safe, cost-effective, and relatively simple procedure.